Recent findings in clinical trials with anti-TSLP monoclonal antibody (tezepelumab) in uncontrolled severe asthma patients showed a significant reduction in asthma exacerbations and improved symptoms, an effect that was not confined to participants with eosinophilic airway inflammation (27). The gene discussed is TSLP; the disease is asthma.